Isomorphic Labs Raises $2.1B Series B — Largest AI Drug Discovery Round Ever

Overview

Isomorphic Labs, the AI drug design company spun out of Google DeepMind, closed a $2.1 billion Series B on May 12, 2026 — one of the largest private funding rounds ever for AI-driven drug discovery. Thrive Capital led the round, joined by existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. Total capital raised now stands at approximately $2.6 billion.

The AI Drug Design Engine

Founded in late 2021 as a standalone spinout from DeepMind, Isomorphic Labs aims to reimagine drug discovery as an end-to-end engineering problem. Its core platform, the IsoDDE (Isomorphic AI Drug Design Engine), builds directly on AlphaFold — the Nobel Prize-winning protein structure prediction system — to accelerate every stage of drug development, from target identification and compound optimization to clinical candidate selection.

Use of Proceeds

• IsoDDE expansion: Enhancing model capabilities and growing global partnerships
• Pipeline acceleration: Advancing proprietary drug candidates toward clinical trials
• Talent: Scaling AI research scientists and medicinal chemists worldwide

Why It Matters

Drug discovery has historically taken 10–15 years and cost over $2 billion per approved drug. AI platforms like IsoDDE aim to compress timelines dramatically by predicting protein-ligand interactions and automating iterative design cycles that previously required years of wet-lab experimentation. The $2.1B round signals that major institutional investors view AI drug discovery as moving from proof-of-concept to production scale — not a future bet, but a present commercial reality.

Source: Isomorphic Labs official announcement